Literature DB >> 20824450

Quality of life and rare diseases.

Luis Rajmil1, Lilisbeth Perestelo-Pérez, Michael Herdman.   

Abstract

HRQOL assessment in patients with rare diseases can help to identify health needs, to evaluate the impact of disease and treatments, and to assess the evolution in health status through the natural history of disease. Several studies have shown that although some rare diseases do not necessarily affect life expectancy, the majority lead to physical, emotional and/or psychosocial limitations with a wide range of disabilities. Reliability as well as content, criterion, and construct validity, and also responsiveness should be taken into account in selecting the instrument to be used assessing individuals with rare diseases. The use of proxy-report may be essential in some cases where the patient is cognitively impaired or unable to communicate. Criteria for selecting a HRQOL instrument, as well as the more common strategies proposed help interpret scores on HRQOL instruments are addressed in the chapter. Given the impact of rare diseases on the quality of life of both patients and carers, it is likely that interest in its measurement will continue to increase among professionals, patients, and the general public. Improving the quality of life of people with rare diseases should be one of the most important goals of any health care intervention or multidisciplinary approach.

Entities:  

Mesh:

Year:  2010        PMID: 20824450     DOI: 10.1007/978-90-481-9485-8_15

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

1.  Development of an Arabic version of the National Eye Institute Visual Function Questionnaire as a tool to study eye diseases patients in Egypt.

Authors:  Nizar Saleh Abdelfattah; Mohamed Amgad; Ahmed A Salama; Marina E Israel; Ghada A Elhawary; Ahmed E Radwan; Mohamed M Elgayar; Tamer M El Nakhal; Islam T Elkhateb; Heba A Hashem; Doha K Embaby; Amira A Elabd; Reem K Elwy; Magdi S Yacoub; Hamdy Salem; Mohamed Abdel-Baqy; Ahmad Kassem
Journal:  Int J Ophthalmol       Date:  2014-10-18       Impact factor: 1.779

2.  Health-related quality of life among children, adolescents, and adults with bladder exstrophy-epispadias complex: a systematic review of the literature and recommendations for future research.

Authors:  Michaela Dellenmark-Blom; Sofia Sjöström; Kate Abrahamsson; Gundela Holmdahl
Journal:  Qual Life Res       Date:  2019-02-06       Impact factor: 4.147

Review 3.  Impact of three genetic musculoskeletal diseases: a comparative synthesis of achondroplasia, Duchenne muscular dystrophy and osteogenesis imperfecta.

Authors:  Maman Joyce Dogba; Frank Rauch; Erin Douglas; Christophe Bedos
Journal:  Health Qual Life Outcomes       Date:  2014-10-25       Impact factor: 3.186

4.  Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia.

Authors:  Lydia Forestier-Zhang; Laura Watts; Alison Turner; Harriet Teare; Jane Kaye; Joe Barrett; Cyrus Cooper; Richard Eastell; Paul Wordsworth; Muhammad K Javaid; Rafael Pinedo-Villanueva
Journal:  Orphanet J Rare Dis       Date:  2016-11-28       Impact factor: 4.123

5.  Reconfiguring Social Value in Health Research Through the Lens of Liminality.

Authors:  Agomoni Ganguli-Mitra; Edward S Dove; Graeme T Laurie; Samuel Taylor-Alexander
Journal:  Bioethics       Date:  2017-02       Impact factor: 1.898

Review 6.  Being the Pillar for Children with Rare Diseases-A Systematic Review on Parental Quality of Life.

Authors:  Johannes Boettcher; Michael Boettcher; Silke Wiegand-Grefe; Holger Zapf
Journal:  Int J Environ Res Public Health       Date:  2021-05-08       Impact factor: 3.390

7.  Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation.

Authors:  Monika Wagner; Hanane Khoury; Jacob Willet; Donna Rindress; Mireille Goetghebeur
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.